Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Kalvista Pharmaceuticals Inc (NQ: KALV ) 11.68 +0.07 (+0.60%) Streaming Delayed Price Updated: 9:57 AM EDT, May 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 12,415 Open 11.47 Bid (Size) 11.62 (4) Ask (Size) 11.74 (4) Prev. Close 11.61 Today's Range 11.47 - 11.76 52wk Range 7.210 - 16.88 Shares Outstanding 34,233,643 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News KalVista Pharmaceuticals to Present at Upcoming Investor Conferences May 21, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 02, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Performance YTD -3.87% -3.87% 1 Month +2.10% +2.10% 3 Month -15.36% -15.36% 6 Month +51.10% +51.10% 1 Year +21.29% +21.29% More News Read More KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year May 01, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Recap: KalVista Pharma Q3 Earnings March 11, 2024 Via Benzinga KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors April 22, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference April 03, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 02, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas March 18, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat March 12, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update March 11, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas March 08, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer March 07, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference March 06, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 04, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting February 27, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting February 26, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat February 20, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting February 16, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire 12 Health Care Stocks Moving In Thursday's Pre-Market Session February 15, 2024 Via Benzinga KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants February 15, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire 12 Health Care Stocks Moving In Wednesday's After-Market Session February 14, 2024 Via Benzinga KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants February 14, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday February 14, 2024 Via Benzinga What's Going With Hereditary Angioedema-Focused KalVista Pharmaceuticals Stock On Tuesday? February 13, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 13, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
